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Induction of annexin-1 during TRAIL-induced
apoptosis in thyroid carcinoma cells
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Dear Editor,
Annexin-1 (ANXA1, lipocortin-1) is the first characterized
member of the annexin superfamily of proteins, so called since
their main property is to bind (i.e. to annex) to cellular
membranes in a Ca2þ -dependent manner. Originally described
as a phospholipase A2-inhibitory protein, ANXA1 can
affect many components of the inflammatory reaction besides
the metabolism of arachidonic acid. ANXA1 has recently
been shown to have a role in the apoptosis of inflammatory
cells.1 The overexpression of ANXA1 in U-937 cells2 and in
broncho-alveolar epithelial cells3 promoted apoptosis asso-
ciated with caspase-3 activation. Exogenous ANXA1 stimulated
transient rise in intracellular calcium concentrations accompa-
nied by dephosphorylation of the proapoptotic protein Bad and
apoptosis of neutrophils.4 ANXA1 may also represent an
endogenous ligand mediating engulfment of apoptotic cells.
The protein is recruited to the phosphatidylserine (PS)-rich
domains of apoptotic cell surface. This recruitment requires
caspase activity and the release of intracellular calcium.
Importantly, silencing ANXA1 protein by small interference
RNA (siRNA) resulted in defective tethering and engulfment of
apoptotic cells.5
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) is a member of the tumor necrosis factor (TNF) family
of proteins including FasL, and TNF-a. TRAIL effectively kills
most thyroid cancer cell lines tested, including those originat-
ing from anaplastic carcinomas.6 Given the interest of TRAIL
as a promising new agent against thyroid cancer and the
importance to understand the mechanisms of TRAIL-induced
death, we have investigated the role of ANXA1 in TRAIL-
induced apoptosis in the follicular undifferentiated (FRO)
thyroid carcinoma cell line.
First, we checked the ability of TRAIL to induce apoptosis of
FRO cells. Time-course experiments showed that 5 ng/ml
TRAIL induced a significant apoptosis at 8 h with a peak at
24 h (Figure 1a). Apoptosis was measured as percent
hypodiploid nuclei by flow cytometry. To confirm the pro-
apoptotic role of TRAIL, the activity of caspase-3 was
measured by fluorimetric assay. Figure 1b shows that a
robust stimulation of caspase-3 activity was caused by 5 ng/ml
TRAIL as early as 3 h with a peak at 24 h incubation. Next, the
effects of TRAIL on ANXA1 expression were investigated by
Western blot analysis. TRAIL (5 ng/ml) stimulated the
cytosolic expression of ANXA1 in a time-dependent fashion
with a peak at 24 h (3.3-fold increase versus 0 time, Po0.001;
Figure 1c). Interestingly, between 0 and 8 h after TRAIL, no
ANXA1 signal could be detected on the membrane of FRO
cells. Conversely, a remarkable ANXA1 expression on FRO
cell membrane was observed at 24 h after TRAIL (Figure 1c).
As ANXA1 may induce apoptosis through Bad dephosphory-
lation,4 the levels of both Bad and phospho-Bad proteins were
measured by Western blot after TRAIL stimulation. Figure 1c
shows that phospho-Bad levels decreased with time and were
barely detectable at 24 h after TRAIL. Bad levels were not
modified by the TRAIL treatment. In order to further
investigate the role of ANXA1 in TRAIL-induced apoptosis,
the technique of siRNAs was utilized. FRO cells were
transfected using oligofectamine with siRNAs designed
against ANXA1 or with a scrambled siRNA and then
challenged with 5 ng/ml TRAIL for 8 h (Figure 1d). In control
cells, TRAIL upregulated ANXA1 expression and inhibited
phospho-Bad expression (lane 2). siRNAs directed against
ANXA1 strongly inhibited ANXA1 expression in both unsti-
mulated and TRAIL-treated cells (lanes 5 and 6). In these
cells, the downregulation of ANXA1 expression by siRNAs
was accompanied by increased expression of phospho-Bad.
In fact, phospho-Bad levels in cells transfected with siRNAs
against ANXA1 (lane 5¼ 76.771.2; lane 6¼ 81.670.7),
measured by densitometry of the ratio phospho-Bad/Bad,
were significantly increased compared to TRAIL-stimulated
control cells (lane 2¼ 21.370.9, Po0.001) and scramble
siRNA-transfected cells (lane 4¼ 21.371.5, Po0.001).
Scrambled siRNAs had no effect on ANXA1 and phospho-
Bad expression. These results strongly suggest that Bad
phosphorylation/dephosphorylation may be modulated by
ANXA1 expression levels.
We then analyzed the effects of ANXA1 siRNAs on TRAIL-
induced apoptosis, measured as appearance of hypodiploid
nuclei. Cells were transfected with or without scrambled or
ANXA1 siRNAs as described and then challenged with 5 ng/
ml TRAIL for 24 h. Figure 1e shows that TRAIL-induced cell
death was unaffected in cells transfected with scrambled
siRNAs. Conversely, in FRO cells transfected with siRNAs
against ANXA1, TRAIL-induced apoptosis was partially
inhibited (26%, Po0.05). The effects of siRNAs were
confirmed by assessment of caspase-3 activity measured 3,
6 and 24 h after TRAIL stimulation (Figure 1f). Again
transfection with scrambled siRNAs had no effect on
caspase-3 activity at all times. On the other hand, TRAIL-
induced caspase-3 activity was partially reduced in FRO cells
transfected with siRNAs against ANXA1 at all times con-
sidered: 3 h, 22%, Po0.01; 6 h, 24%, Po0.001; 24 h,
25%, Po0.001.
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Figure 1 (a) Time-dependent apoptosis induced by TRAIL (5 ng/ml) in FRO thyroid carcinoma cells. Apoptosis was measured as percentage of hypodiploid nuclei by
propidium iodide staining. Cells (2 105) were washed in phosphate-buffered saline (PBS) and resuspended in 500 ml of a solution containing 0.1% sodium citrate, 0.1%
Triton X-100 and 50 mg/ml propidium iodide. After incubation at 41C for 30 min in the dark, cell nuclei were analyzed with Becton Dickinson FACScan flow cytometer. (b)
Time-dependent activation of caspase-3 by TRAIL (5 ng/ml). Caspase-3 activity was measured by fluorimetric assay. Cells (2 106) were lysed in a buffer containing
10 mmol/l Tris (pH 7.5), 130 mmol/l NaCl, 1% Triton X-100, 10 mmol/l NaPi and 10 mmol/l NaPPi; 20 mg protein was then incubated with 20 mmol/l Ac-DEVD-AMC
(Becton Dickinson, Milan, Italy) in a buffer containing 20 mmol/l HEPES (pH 7.5), 10% glycerol and 2 mmol/l dithiothreitol (DTT) at 371C for 2 h. The release of AMC was
monitored in a spectrofluorimeter with an excitation wavelength of 380 nm and emission wavelength range of 430–460 nm. (c) Effect of TRAIL on the expression of
ANXA1, Bad and phospho-Bad (p-Bad) in FRO cells. Cells were plated at a density 5 106/ml and incubated with or without TRAIL (5 ng/ml) at different times. A 30 mg
portion of proteins from the cell extracts was analyzed by Western blot using polyclonal anti-ANXA1 antibodies or commercially available anti-p-Bad or anti-Bad
polyclonal antibodies (Cell Signaling, CELBIO, Milan, Italy). Immunoreactive bands were quantified by densitometry. Membrane proteins were obtained in 5 mM EDTA-
Tris-HCl, which acts as a Ca2þ chelating agent and removes ANXA1 attached to cell surface. A 30 mg portion of proteins was then analyzed by Western blot as above.
(d) Effect of siRNAs against ANXA1 on the expression levels of ANXA1, Bad and phospho-Bad (p-Bad) in unstimulated and TRAIL-stimulated FRO cells. siRNAs with
two thymidine residues (dTdT) at 30 end of the sequences were designed for two sequences for ANXA1 – Annexin 1(A) (sense 50-CAGCGUCAACAGAUCAAAG-30) and
Annexin 1(B) (sense 50-CCGAUCUGAGGACUUUGGU-30) – gene along with their corresponding antisense RNA oligonucleotides as described (Dharmacon Research
Inc., Lafayette, CO, USA). siRNA oligo scrambled KROAA-006461 (sense 50-CAGUCGCGUUUGCGACUGG-30) (Dharmacon Research Inc., Lafayette, CO, USA) was
used as control of siRNA-ANXA1 at 100 nM final concentration. Approximately, 1.5 105 cells were plated in six-well plates at 30–50% confluency in media containing
10% FBS. Transfection of RNA oligonucleotides (siRNAs) was performed using oligofectamine (Invitrogen, Milan, Italy), following the protocols provided by the
manufacturer, to result in a final RNA (a, b) mixture of concentration 100 nM. At 72 h after transfection, the cells were treated with TRAIL (5 ng/ml) for 8 h. Western blot
analysis was performed on 30 mg protein extracts as described above. Immunoreactive bands were quantified by densitometry. (e) siRNAs against ANXA1 partially
inhibited TRAIL-induced apoptosis in FRO cells. Transfection was performed as above. Apoptosis was analyzed by propidium iodide staining as described previously
after 24 h incubation with or without TRAIL (5 ng/ml). (f) siRNAs against ANXA1 partially inhibited TRAIL-induced caspase-3 activity in FRO cells. Transfection was
performed as above. Caspase-3 activity was measured by fluorimetric assay as described above at the indicated times with or without TRAIL (5 ng/ml). All data are
means7S.E.M. of three experiments performed in triplicate. Bonferroni test: **Po0.01 versus 0 time (a) or versus medium (e); ***Po0.001 versus 0 time (a, b) or
versus medium (e, f); #Po0.05 versus TRAIL and TRAILþ scrambled (e); ##Po0.01 versus 3 h TRAIL and TRAILþ scrambled (f); ###Po0.001 versus TRAIL and
TRAILþ scrambled (d) or versus 6–24 h TRAIL and TRAILþ scrambled (f)
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These results show for the first time that in FRO cells TRAIL
is able to upregulate ANXA1 expression and induce the
translocation of the protein to the membranes of apoptotic
cells. The time course of the upregulation of ANXA1
expression by TRAIL correlates well with the stimulation of
both caspase-3 activity and cell death caused by TRAIL.
Furthermore, the inhibition of ANXA1 expression by siRNAs
leads to a partial, but statistically significant reduction of
TRAIL-induced apoptosis, suggesting that ANXA1 expression
may contribute to the proapoptotic effects of TRAIL. The
upregulation of ANXA1 expression by TRAIL may be due to
transcriptional activation. ANXA1 promoter has an AP-1 site
that can be stimulated by phorbol esters to induce gene
expression of the protein.7 It is also known that DR5 ligation by
TRAIL mediates AP-1 activation to induce gene expression of
proteins like IL-8 that possess AP-1 motifs in their promoters.8
The mechanism(s) of ANXA1 gene transcriptional activation
by TRAIL are currently under investigation in our laboratory.
It has been shown that exogenous ANXA1 is able to induce
neutrophil death through intracellular calcium increase and
BAD dephosphorylation. This allows BAD to associate with
mitochondria, heterodimerize with Bcl-XL and promote
apoptosis.4 The present data support the hypothesis that in
FRO cells ANXA1 may promote apoptosis by reducing the
phosphorylation levels of Bad. No evidence is currently
available as to which phosphatase, if any, might be activated
by ANXA1 to dephosphorylate Bad.
Finally, the membrane expression of ANXA1 after 24 h
TRAIL (Figure 1c) confirms previous results in Jurkat cells5
and suggests that the exposure of ANXA1 on the surface of
apoptotic cells may be a widespread mechanism for the
recognition and removal of apoptotic cells not restricted to a
single cell type. Further work is necessary to clarify the role
of ANXA1 as ‘eat me’ signal in FRO cells.
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